PLG0301

PLG0301 is a cationic antibacterial peptide developed by Peptilogics for the treatment of lung infections associated with cystic fibrosis. It is designed to rapidly induce the death of a wide range of bacteria, including multidrug-resistant strains commonly found in airway secretions of individuals with cystic fibrosis. PLG0301 exhibits both anti-bacterial and anti-inflammatory activity, aiming to address major causes of disease progression in cystic fibrosis by reducing pulmonary exacerbations and pathological inflammation. The drug is currently in preclinical development, supported by research funding from the Cystic Fibrosis Foundation[1][2][3][4]. Mechanism of action has not been fully elucidated but likely involves rapid bactericidal activity through disruption of bacterial membranes and potential anti-biofilm effects.